Argus
•
May 13, 2026
RGEN: Lowering target price to $108.00
Summary
Repligen, headquartered in Waltham, Massachusetts, is a global life sciences company that develops and sells bioprocessing equipment and supplies used in the manufacturing of biologic drugs, including monoclonal a
Upgrade to begin using premium research reports and get so much more.
Exclusive reports, detailed company profiles, and best-in-class trade insights to take your portfolio to the next level
UpgradeRelated Reports
LGND: Lowering target price to $244.00
May 13, 2026
•
LGND
GMED: Lowering target price to $84.00
May 13, 2026
•
GMED
MASI: Lowering target price to $187.00
May 13, 2026
•
MASI
NBIX: Raising target price to $171.00
May 13, 2026
•
NBIX
STAA: Raising target price to $30.00
May 13, 2026
•
STAA
